louisnavelliersportfoliograderpro posts

Feed

Can the Pre take on the BlackBerry and iPhone?

The annual Consumer Electronics Show (CES) in Las Vegas was last week. In past years, just the anticipation of the world's largest electronics trade show was enough move technology stocks higher.

That was not the case this year, though, as investors grapple with a weak economy, frozen credit, plunging home values and rising unemployment. Just paying the bills and keeping one's head above water seems to be the order of the day. The market sold off hard last week, and not even the CES could pull it out of its funk. Still, there were some bright spots.

Palm, Inc. (NASDAQ: PALM) gave its investors a taste of the old days as its shares soared 34% after its new touch-screen phone and mobile operating system garnered admiration from analysts and attendees at the CES.

Continue reading Can the Pre take on the BlackBerry and iPhone?

A 'Clear' buy at these levels

Kirkland, Wash. based Clearwire Corporation (NASDAQ: CLWR) closed on a transaction in December which merged the Sprint/Nextel (NYSE: S) wireless Internet business with the WiMax business of CLWR.

In connection with the transaction, CLWR secured $3.2 billion from a group of investors linked to the development of the wireless broadband industry, including Comcast (NASDAQ: CMCSA), Google (NASDAQ: GOOG), Intel (NASDAQ: INTC) and Time Warner Cable (NYSE: TWX).

Clearwater is offering its broadband service under the label "Clear."

While operating in a competitive environment for WiMax (Worldwide Interoperability for Microwave Access), CWTR has an advantage over WiFi, which is limited to access in small areas, such as home or coffee shop. WiMax, on the other hand, offers access from a very broad area and while being mobile in a vehicle.

Though not as capitalized as competitors like Verizon (NYSE: VZ) or AT&T (NYSE: T), the company's relationship with its investors should give it access to capital when needed.

On Jan. 9, due to a significant drop in the market value of CLWR stock, Intel announced a writedown of its investment in CLWR of $950 million. Intel is only the first of the investment group to reflect this writedown in their guidance for the quarter.

Driven by accounting rules mandating that investments in stocks that decline significantly in value be written off, the other publicly traded companies with investments in CLWR will be required to follow suit.

In the face of these writedowns, investors have kept the price of CLWR depressed in spite of recent good news from the company. At around $4.60, the stock is trading near its 52-week low of $3.24, and well below its high of $7.20.

The company's balance sheet reflects its growth mode, with a long-term debt-to-equity ratio of 186 and a current ratio of 3.25.

Continue reading A 'Clear' buy at these levels

Family Dollar comes out on top

It comes as no surprise that the top performer among the stocks comprising the S&P 500 Index is a retailer focused on delivering quality products and services at a discount price.

Family Dollar Stores (NYSE: FDO) increased nearly 30% in 2008, compared with a decrease of 40% in the S&P 500.

Defying the expectations of gloomy analysts who are paralyzed by their inability to value companies during the last 12 months, and by short sellers who perceived a price drop following the high level performance in 2008, the stock is continuing its climb as we enter the 2009 trading year.

Family Dollar reported first quarter earnings Wednesday, which exceeded analysts' expectations and company projections.

Earnings for the period were up by 14%, with revenue increasing by 4.2% and same-store sales up a healthy 2.1%. Market reaction to the report is stunning, with FDO up more than 14% at the close.

Family Dollar CEO Howard Levine, son of founder and Chairman Emeritus Leon Levine, issued a forecast of continued growth for the next quarter and for all of 2009.

The company is now projecting earnings of $1.63 to $1.81 per share for fiscal year 2009. Earlier forecasts were in the range of $1.58 to $1.78. Projections of same-store sales growth for the year were also increased from a range of 1%-3% to 2%-4%.

FDO combines conservative leadership with a consumer-friendly neighborhood store environment, and a product mix appealing to cost-conscious consumers to deliver value and a positive shopping experience. With minimal exposure to price-volatile electronic and apparel inventory, company performance is not likely to be adversely affected by a prolonged economic downturn.

FDO has more than 6,000 locations in 44 contiguous states. The company has effectively managed its rapid growth during the last five years, having opened more than half of its stores during this period.

Continue reading Family Dollar comes out on top

Amgen offers safety, growth in 2009

There were a few stocks in 2008 that exhibited great performance despite horrible market conditions. And these gems of 2008 may provide investors with a safe haven of sorts for 2009.

In fact, we are already hearing analysis of the year to come suggesting that biotechnology stocks will be the place to be for positive returns in the new year.

One such name to consider is Amgen (NASDAQ: AMGN).

Founded in 1980, AMGN is one of the largest biotechnology companies in the market. It has a stable of proven drugs that provides significant profits, and a pipeline of opportunities that should provide reasonable growth in the future.

Shares of AMGN have gained approximately 20% during the last year as investors recognized the value of current profits combined with future growth. Interestingly, the company really gained traction during the second half of the year as the rest of the market was imploding.

Even with the gains, AMGN is a compelling investment story.

Shares trade for 15 times trailing earnings and only 12 times forward earnings. That means you can buy shares for a price-to-earnings ratio that is lower than its growth rate.

One reason for the optimism in the stock in 2008 was the progress made on its osteoporosis drug, Denosumab. Analysts are expecting the drug to be a blockbuster.

Denosumab has done well in trials, and AMGN recently applied for FDA approval to bring the drug to market. Given the expected 10-month FDA review and processing period, AMGN is only a year or so away from the sales benefits of this new drug.

Continue reading Amgen offers safety, growth in 2009

< Previous Page

Symbol Lookup
IndexesChangePrice
DJIA-74.9212,454.83
NASDAQ-1.852,837.53
S&P 500-2.861,317.82

Last updated: May 28, 2012: 06:04 PM

Hot Stocks

General Electric

19.20-0.05(-0.26)

Alcoa

8.630.00(0.00)

Apple Inc

562.29-3.03(-0.54)

Google Inc 'A'

591.53-12.13(-2.01)

Bank of America

7.15+0.01(+0.14)

Wal-Mart Stores

65.31+0.24(+0.37)

Exxon Mobil Corp

82.08-0.53(-0.64)

Ford

10.60+0.01(+0.09)

Citigroup

26.47-0.19(-0.71)

IBM

194.30-1.79(-0.91)

Yahoo

15.36+0.01(+0.07)

Starbucks

54.56-0.20(-0.37)

Microsoft

29.06-0.01(-0.03)

Home Depot

49.44-0.27(-0.54)

DailyFinance Headlines

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

Page Loaded in 1338242671973 ms.